Could a daily pill stop HHT nosebleeds? new trial investigates.
Disease control
Ongoing
This study tests whether a low dose of the drug pazopanib, taken daily for 24 weeks, can reduce the severity and duration of nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). About 70 participants will receive either the active drug or a placebo. The research…
Phase: PHASE2, PHASE3 • Sponsor: Cure HHT • Aim: Disease control
Last updated May 13, 2026 16:02 UTC